iPLATO is a London-based Health Tech company working in partnership with clinicians to help healthcare commissioners transform patient care.
Established in 2006, iPLATO’s solutions have proven to improve patient access to healthcare and early diagnosis, enabling powerful health promotions, to support people living with long-term conditions. Currently connecting over 20 million patients in partnership with thousands of clinicians, iPLATO has emerged as a British leader in Health Tech.
Across the iPLATO network, healthcare professionals run campaigns to promote stop smoking, weight loss, childhood immunisation and pandemic awareness as well as mobile disease management services for people with diabetes, hypertension, epilepsy and HIV.
Executive Management Profiles
Tobias Alpsten – CEO
As iPLATO’s Chief Executive Officer, Tobias Alpsten is responsible for setting overall strategy and for leading marketing, support, product management and engineering.
Committed to evidence based interventions in healthcare, Tobias works with leading institutions including UCL, Imperial College, the Department of Health and Public Health England on increasing the evidence base for Health Tech through research.
After studies in Stockholm and Paris, Tobias earned an MSc in Electrical Engineering and Information Technology in 1996. Tobias joined Accenture’s Paris office before founding iPLATO in London in 2000. He has worked in Sweden, France, Ireland, Singapore, Japan, the US, and now the UK.
Martin Rowden – COO, CFO & Co-Founder
Martin is the co-founder and Chief Operations Officer, Chief Financial Officer and Co-Founder of iPLATO, serving on the Board of Directors and Executive staff. Martin is a renowned entrepreneur with a vast amount of regional and international experience covering a variety of functions from operational and sales to marketing and strategy. He thrives in a connected world, whereby, being more digital is fundamental to overcoming the challenges presented by the economics of an ageing population and rising levels of chronic disease.
Since founding iPLATO with Tobias in 2005, Martin has been at the forefront of developing and bringing to market practical mHealth solutions that are an integral component of the wider Digital Health opportunity. In the last decade, the company has launched its bespoke solutions with over 2,500 healthcare organisations in the UK and US. Today, the company’s products are connecting over 10,000,000 patients with their healthcare provider.
Martin has a Bachelor’s degree in Economics and is a qualified Chartered Accountant (ACA).
Mike Lewis – Executive Chairman
Mike Lewis joined iPLATO as Chairman in February 2013 bringing over 25 years of global Health industry experience to the company.
Having previously been EMEA President of medical device company Gambro with responsibility for $1.3Billion in sales and 1000 direct staff he also was Head of Global Marketing, Strategy and Product Development. Gambro was subsequently sold for $3,9Bn to private equity company EQT/Investor.
He has also held senior roles in operations, general management, strategy, marketing and sales at Align Technology (based in Amsterdam), Boston Scientific (based in Paris), C.R. Bard (based in New Jersey), Sybron (based in Switzerland) and Becton Dickinson, Merck and Sandoz (based in the UK).
Currently, he is Chair of 5 public and private healthcare and digital companies, Chairs the Assisted Living Innovation Platform, is a member of the Biocatalyst Major Awards Panel, mentors for Cambridge Enterprise, Chairs the KTN MedTech Board and also acts as healthcare advisor for multiple private equity companies.
Mark Leonard – Head of Technology
Mark Leonard has over 16 years in technical programme and project management, he is also an experienced Scrum Master in the health, defence and mobile hardware sectors.
He is fully versed in Agile, Waterfall and Kanban software development methodologies. His experience and certifications include: Scrum, Capability Maturity Model, ISO9000-3, Prince 2, AQAP 13, DOD 2167A.
Please click here to view members of The iPLATO Clinical Advisory Board (CAB).